Biotechnology

Affimed NV

Affimed N.V. Delays Annual Report Due to Liquidity Issues

Affimed N.V. shares latest progress on AFM24 at AACR Annual Meeting

Affimed N.V. Abstracts to be Presented at ASCO Annual Meeting

Affimed N.V. Receives NASDAQ Below Minimum Bid Price Notice

FDA Grants RMAT Certification to Affimed and Artiva's Lymphoma Combination Therapy

Affimed NV released FY2024 Q3 earnings on November 14 During-Market (EST), actual revenue 183.12 KUSD (forecast 1.466 MUSD), actual EPS -1.0499 USD (forecast -1.0589 USD)

Affimed NV released FY2024 Cumulative 3Q earnings on November 14 During-Market (EST), with actual revenue of 766.34K USD and EPS of -3.4992

Affimed NV to Release FY2024 Q3 Earnings on November 14 During Market Hours (EST), Forecast Revenue 1.39 M USD, EPS -1.0589 USD

Affimed N.V. to Present AFM28 Clinical Data at ASH Annual Meeting

Affimed N.V. Appoints Shawn Leland as New CEO

Affimed Announces Q1 2024 Financial Results and Clinical Project Updates

BNP Paribas increases stake in Affimed

Affimed announces positive data from AFM24-102 trial in non-small cell lung cancer patients

Affimed N.V. receives FDA fast track designation

Analyst Lee Watsek from Cantor Fitzgerald Reaffirms Overweight Rating on Affimed (NASDAQ: AFMD)

Vision Marine Tech

SRX Health Solutions

AMC Robotics

Cementos Pacasmayo Saa 

Everbright Digital

B Riley Financial

Rezolve AI

Emerald

Venus Concept

Aldeyra Therap

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Argenx

Alnylam Pharma

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap